ClinicalTrials.gg
CompletedNCT02320721SENIORUpdated Apr 21, 2020Results posted

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

A Phase 3 interventional study of Insulin Glargine (HOE901 - U300) and Insulin Glargine (HOE901 - U100) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 162 sites in 18 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,014
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
7th of 175
1,014 · median 253
Started
2015
with 13 others
Phase 3
60 of 176
1 open now
Registered
120th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 60 in phase 3, and was the 120th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the non-inferiority of H0E901-U300 to Lantus, in change of glycated hemoglobin A1c (HbA1c).

Secondary Objectives:

To demonstrate the superiority of H0E901-U300 in comparison with Lantus in:

  • Percentage of participants with at least one severe and/or confirmed (by plasma glucose ≤70mg/dL [3.9mmol/L]) hypoglycemia event from 22:00 to 08:59 next morning
  • Percentage of participants with at least one nocturnal (from 00:00-05:59) severe and/or confirmed (≤70mg/dL [3.9mmol/L]) hypoglycemia event
  • Percentage of participants with at least one severe and/or confirmed (by plasma glucose ≤70mg/dL [3.9mmol/L]) hypoglycemia event occurring at any time of day
  • HbA1c change
Read the detailed description

The study consisted of a 4-week screening period, a 26-week treatment period comparing HOE901-U300 to Lantus, and a 2-day safety follow-up period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ≥65 years old with type 2 diabetes mellitus, inadequately controlled on antidiabetic regimens either including no insulin, or with basal insulin as their only insulin.
  • Signed .

Exclusion criteria

Exclusion criteria:

  • at screening visit:

    • \<7.0% or >10.0% for participants taking basal insulin.
    • \<7.5% or >11.0% for insulin-naïve participants.
  • History of type 2 diabetes mellitus for less than 1 year before screening.
  • Participants not on stable basal insulin dose (±10% in the last 8 weeks prior to screening visit).
  • Change in dose of antidiabetic treatment or initiation of new glucose-lowering medications in the last 8 weeks prior to screening.
  • Chronic (>10 days continuous use in previous 6 months) use of bolus insulin injections, whether given separately or as part of a combination with basal insulin, e.g. premix insulin; For insulin-naïve individuals: current or previous insulin use except for a maximum of 10 consecutive days (e.g. acute illness, surgery) during the last year prior to screening.
  • Cognitive disorder and dementia assessed clinically and by (MMSE) score \<24, or any neurologic disorder that would likely affect the participant's ability to follow the study procedure. The participant would be eligible despite an MMSE score \<24 if the investigator determined that the low score reflected educational or cultural background and not dementia as long as the participant was otherwise able to meet the study requirements.
  • Participants who had end-stage renal disease (\<15 mL/min/1.73m\^2, per estimated (eGFR) measurement by Modification of Diet in Renal Disease (MDRD).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,014 participants (actual)

Study arms

  • Experimental
    HOE901-U300

    HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.

    Drug: Insulin Glargine (HOE901 - U300) · Drug: Background therapy

  • Active comparator
    Lantus

    Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.

    Drug: Insulin Glargine (HOE901 - U100) · Drug: Background therapy

Interventions

  • Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).

    Also known as: Toujeo®

  • Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).

    Also known as: Lantus®

  • DrugBackground therapy

    Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Week 26

    Adjusted least square (LS) means were obtained from analysis of covariance (ANCOVA) after multiple imputation of missing data including post baseline HbA1c data during the 26-week randomized period.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period

    Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

    Time frame: Baseline up to Week 26

  2. Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period

    Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

    Time frame: Baseline up to Week 26

  3. Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period

    Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

    Time frame: Baseline up to Week 26

  4. Percentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period

    Participants without any available HbA1c assessment at Week 26 were considered as non-responders in the analyses.

    Time frame: Baseline up to Week 26

  5. Percentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period

    Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

    Time frame: Baseline up to Week 26

  6. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

    Adjusted LS means from multiple imputation approach including post baseline values during the 26-week randomized period.

    Time frame: Baseline, Week 26

  7. Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26

    WHO-5 well-being index evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions, each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score was transformed into a percentage score ranging from 0 (worst possible quality of life) to 100 (best possible quality of life).

    Time frame: Baseline, Week 26

  8. Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment

    Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 14) values were used to determine the requirement of rescue medication. Threshold values at Week 14: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.

    Time frame: Baseline up to Week 26

Other outcomes

  1. Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) During the 26 Weeks of Treatment

    Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).

    Time frame: Baseline up to Week 26

  2. Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment

    Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).

    Time frame: Baseline up to Week 26

07

Results

Posted Jul 11, 2017

Participant flow

The study was conducted at 162 study centers across 18 countries. A total of 1515 participants were screened between 16 January 2015 and 14 October 2015, of whom 501 were screen failures.

Participant flow — Overall Study
MilestoneHOE901-U300Lantus
Started508506
Treated (safety population)508505
Completed481472
Not completed2734
Withdrew: Adverse event66
Withdrew: Lack of efficacy20
Withdrew: Poor compliance to protocol37
Withdrew: Randomized but not treated01
Withdrew: Hypoglycemia10
Withdrew: Other than specified above1520

Outcome measures

PrimaryChange in HbA1c From Baseline to Week 26

Adjusted least square (LS) means were obtained from analysis of covariance (ANCOVA) after multiple imputation of missing data including post baseline HbA1c data during the 26-week randomized period.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of hemoglobin
Change in HbA1c From Baseline to Week 26
percentage of hemoglobinHOE901-U300Lantus
Change in HbA1c From Baseline to Week 26-0.89 ± 0.038-0.91 ± 0.042
Statistical analysis
  • HOE901-U300 vs Lantus · Ls mean difference: 0.02 · 95% CI -0.092 to 0.129
SecondaryPercentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period

Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period
percentage of participantsHOE901-U300Lantus
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (22:00 to 08:59 Hours Next Morning) During 26-Week Randomized Period48.347.7
Statistical analysis
  • HOE901-U300 vs Lantus · Cochran-Mantel-Haenszel · p = 0.8415 (Threshold for significance at 0.05 level.) · Relative risk: 1.01 · 95% CI 0.890 to 1.153
SecondaryPercentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period

Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period
percentage of participantsHOE901-U300Lantus
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Nocturnal Hypoglycemia (00:00 to 05:59 Hours) During 26-Week Randomized Period20.222.5
SecondaryPercentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period

Estimated percentages from multiple imputation approach including data from the 26-week randomized period. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period
percentage of participantsHOE901-U300Lantus
Percentage of Participants With At Least One Severe and/ or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia Occurring at Any Time of the Day During 26-Week Randomized Period59.462.7
SecondaryPercentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period

Participants without any available HbA1c assessment at Week 26 were considered as non-responders in the analyses.

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.5% or HbA1c <7% During 26-Week Randomized Period
percentage of participantsHOE901-U300Lantus
HbA1c <7.5%60.658.9
HbA1c <7.0%33.335.2
SecondaryPercentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period

Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose ≤3.9 mmol/L (70 mg/dL).

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.5% or <7.0% at Week 26 and No Severe and/or Confirmed (≤3.9 mmol/L [70 mg/dL]) Hypoglycemia During 26-Week Randomized Period
percentage of participantsHOE901-U300Lantus
HbA1c <7.5%26.421.5
HbA1c <7.0%14.012.3
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Week 26

Adjusted LS means from multiple imputation approach including post baseline values during the 26-week randomized period.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
mmol/LHOE901-U300Lantus
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26-1.68 ± 0.122-1.77 ± 0.135
SecondaryChange in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26

WHO-5 well-being index evaluates positive psychological well-being during the past 2 weeks and consists of 5 questions, each rated on a 6-point Likert scale from 0 (not present) to 5 (constantly present). Total raw score was transformed into a percentage score ranging from 0 (worst possible quality of life) to 100 (best possible quality of life).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · scores on a scale
Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26
scores on a scaleHOE901-U300Lantus
Change in World Health Organization-5 (WHO-5) Well-Being Questionnaire Percentage Score From Baseline to Week 26-1.16 ± 0.7510.22 ± 0.758
SecondaryPercentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment

Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after Week 14) values were used to determine the requirement of rescue medication. Threshold values at Week 14: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment
percentage of participantsHOE901-U300Lantus
Percentage of Participants Requiring Rescue Therapy Over the 26 Weeks of Treatment3.72.6
Other pre-specifiedPercentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) During the 26 Weeks of Treatment

Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) During the 26 Weeks of Treatment
percentage of participantsHOE901-U300Lantus
Any hypoglycemia62.666.5
Documented symptomatic hypoglycemia32.934.7
Severe and/or confirmed hypoglycemia58.160.6
Severe and/or confirmed hypoglycemia:<75 years age59.260.9
Severe and/or confirmed hypoglycemia:≥75 years age54.859.4
Other pre-specifiedHypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment

Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).

Time frame:
Baseline up to Week 26
Reported as:
Number · events per participant year
Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year During the 26 Weeks of Treatment
events per participant yearHOE901-U300Lantus
Any hypoglycemia6.067.74
Documented symptomatic hypoglycemia1.852.56
Severe and/or confirmed hypoglycemia5.176.36
Post-hocHypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year: By Age Categorical Data During the 26 Weeks of Treatment

Hypoglycemia events were hypoglycemia of any category, severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); documented symptomatic hypoglycemia (symptoms of hypoglycemia with plasma glucose ≤3.9 mmol/L \[70 mg/dL\]); confirmed hypoglycemia (with or without symptoms of hypoglycemia and plasma glucose ≤3.9 mmol/L).

Time frame:
Baseline up to Week 26
Reported as:
Number · events per participant year
Hypoglycemia (Any Hypoglycemia, Documented Symptomatic Hypoglycemia, Severe and/or Confirmed Hypoglycemia) Event Rate Per Participant Year: By Age Categorical Data During the 26 Weeks of Treatment
events per participant yearHOE901-U300Lantus
Any hypoglycemia:<75 years age6.447.85
Any hypoglycemia:≥75 years age5.017.32
Documented symptomatic hypoglycemia:<75 years age2.112.52
Documented symptomatic hypoglycemia:≥75 years age1.122.71
Severe and/or confirmed hypoglycemia:<75 years age5.436.37
Severe and/or confirmed hypoglycemia:≥75 years age4.466.28

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 184) regardless of seriousness or relationship to IMP.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HOE901-U3001/508 (0.2%)41/508 (8.1%)62/508 (12.2%)
Lantus0/505 (0%)34/505 (6.7%)64/505 (12.7%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventHOE901-U300Lantus
PneumoniaInfections and infestations1/5083/505
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/5081/505
Atrial fibrillationCardiac disorders0/5082/505
Coronary artery diseaseCardiac disorders2/5082/505
PyelonephritisInfections and infestations0/5082/505
Hypertensive crisisVascular disorders1/5082/505
Acute myocardial infarctionCardiac disorders2/5081/505
Angina unstableCardiac disorders2/5080/505
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/5080/505
Ischaemic strokeNervous system disorders2/5080/505
Most frequent other events
Most frequent other events
EventHOE901-U300Lantus
NasopharyngitisInfections and infestations37/50838/505
Upper respiratory tract infectionInfections and infestations27/50828/505

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)HOE901-U300LantusTotal
Mean71.1 ± 4.970.8 ± 4.871.0 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)HOE901-U300LantusTotal
Female258229487
Male250277527
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)HOE901-U300LantusTotal
Mean30.9 ± 5.531.2 ± 5.731.1 ± 5.6
Duration of Type 2 Diabetes
Duration of Type 2 Diabetes(years)HOE901-U300LantusTotal
Mean15.29 ± 8.1715.35 ± 7.7015.32 ± 7.93
Baseline Glycated Hemoglobin A1c (HbA1c)
Baseline Glycated Hemoglobin A1c (HbA1c)(percentage of HbA1c)HOE901-U300LantusTotal
Mean8.20 ± 0.918.22 ± 0.928.21 ± 0.91
Randomization strata of insulin
Randomization strata of insulin(Participants)HOE901-U300LantusTotal
Insulin-naive166165331
Insulin pre-treated342341683
Age Group
Age Group(Participants)HOE901-U300LantusTotal
<75 years of age373400773
≥75 years of age135106241
08

Study locations

162 sites
  • Investigational Site Number 840058
    Saraland, Alabama 36571, United States
  • Investigational Site Number 840019
    Fresno, California 93720, United States
  • Investigational Site Number 840021
    Fresno, California 93722, United States
  • Investigational Site Number 840040
    Greenbrae, California 94904, United States
  • Investigational Site Number 840070
    Huntington Park, California 90255, United States
  • Investigational Site Number 840064
    Los Angeles, California 90057, United States
  • Investigational Site Number 840031
    Norwalk, California 90650, United States
  • Investigational Site Number 840065
    Oakland, California 94612, United States
  • Investigational Site Number 840050
    Orange, California 92868, United States
  • Investigational Site Number 840036
    Simi Valley, California 93065, United States
  • Investigational Site Number 840003
    Temecula, California 92591, United States
  • Investigational Site Number 840062
    Walnut Creek, California 94598, United States
  • Investigational Site Number 840027
    Longmont, Colorado 80501, United States
  • Investigational Site Number 840030
    Bradenton, Florida 34208, United States
  • Investigational Site Number 840010
    Miami, Florida 33156, United States
  • Investigational Site Number 840035
    Miami, Florida 33156, United States
  • Investigational Site Number 840014
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840051
    Ocoee, Florida 34761, United States
  • Investigational Site Number 840056
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840007
    Saint Petersburg, Florida, United States
  • Investigational Site Number 840041
    Roswell, Georgia 30076, United States
  • Investigational Site Number 840053
    Statesboro, Georgia 30461, United States
  • Investigational Site Number 840042
    Woodstock, Georgia 30189, United States
  • Investigational Site Number 840005
    Arlington Heights, Illinois 60005, United States
  • Investigational Site Number 840004
    Peoria, Illinois 61602, United States
  • Investigational Site Number 840029
    Springfield, Illinois 62704, United States
  • Investigational Site Number 840013
    Avon, Indiana 46123, United States
  • Investigational Site Number 840023
    Avon, Indiana 46123, United States
  • Investigational Site Number 840039
    Evansville, Indiana 47714, United States
  • Investigational Site Number 840006
    Muncie, Indiana 47304, United States
  • Investigational Site Number 840026
    Des Moines, Iowa 50314, United States
  • Investigational Site Number 840033
    West Des Moines, Iowa 50266, United States
  • Investigational Site Number 840032
    Overland Park, Kansas 66209, United States
  • Investigational Site Number 840069
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840020
    Flint, Michigan 48504, United States
  • Investigational Site Number 840037
    Nashua, New Hampshire 03063, United States
  • Investigational Site Number 840018
    New York, New York 10001, United States
  • Investigational Site Number 840048
    Asheville, North Carolina 28805, United States
  • Investigational Site Number 840009
    Charlotte, North Carolina 28209, United States
  • Investigational Site Number 840011
    Greensboro, North Carolina 27408, United States
  • Investigational Site Number 840047
    Greenville, North Carolina 27834, United States
  • Investigational Site Number 840016
    Salisbury, North Carolina 28144, United States
  • Investigational Site Number 840012
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840022
    Fargo, North Dakota 58103, United States
  • Investigational Site Number 840072
    Cincinnati, Ohio 45219, United States
  • Investigational Site Number 840054
    Wadsworth, Ohio 44281, United States
  • Investigational Site Number 840067
    Bend, Oregon 97702, United States
  • Investigational Site Number 840057
    Corvallis, Oregon 97330, United States
  • Investigational Site Number 840045
    Feasterville, Pennsylvania 19053, United States
  • Investigational Site Number 840017
    Pittsburgh, Pennsylvania 15220, United States
  • Investigational Site Number 840059
    Greenville, South Carolina 29605, United States
  • Investigational Site Number 840015
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840002
    Chattanooga, Tennessee 37404, United States
  • Investigational Site Number 840046
    Chattanooga, Tennessee 37404, United States
  • Investigational Site Number 840034
    Knoxville, Tennessee 37912, United States
  • Investigational Site Number 840055
    Arlington, Texas 76014, United States
  • Investigational Site Number 840001
    Dallas, Texas 75230, United States
  • Investigational Site Number 840024
    Irving, Texas 75039, United States
  • Investigational Site Number 840061
    North Richland Hills, Texas 76180, United States
  • Investigational Site Number 840028
    Richmond, Texas 77469, United States
  • Investigational Site Number 840063
    San Antonio, Texas 78230, United States
  • Investigational Site Number 840038
    Saint George, Utah 84790, United States
  • Investigational Site Number 840025
    Federal Way, Washington 98003, United States
  • Investigational Site Number 840060
    Bridgeport, West Virginia 26330, United States
  • Investigational Site Number 032001
    Caba, 1120, Argentina
  • Investigational Site Number 032002
    Caba, 1405, Argentina
  • Investigational Site Number 032006
    Capital Federal, 1180, Argentina
  • Investigational Site Number 032004
    Ciudad Autonoma De Buenos Aire, 1206, Argentina
  • Investigational Site Number 032003
    Mar Del Plata, 7602, Argentina
  • Investigational Site Number 036002
    Box Hill, 3128, Australia
  • Investigational Site Number 036004
    Fitzroy, 3065, Australia
  • Investigational Site Number 036001
    Geelong, 3220, Australia
  • Investigational Site Number 036003
    Herston, 4029, Australia
  • Investigational Site Number 124003
    Brampton, L6S 0C9, Canada
  • Investigational Site Number 124005
    Burlington, L7M 4Y1, Canada
  • Investigational Site Number 124008
    Chatham, N7L 1C1, Canada
  • Investigational Site Number 124010
    Mirabel, J7J 2K8, Canada
  • Investigational Site Number 124009
    Montreal, H2X 0A9, Canada
  • Investigational Site Number 124006
    Sainte-Foy, G1W4R4, Canada
  • Investigational Site Number 124004
    Thornhill, L4J 8L7, Canada
  • Investigational Site Number 124002
    Toronto, M4G 3E8, Canada
  • Investigational Site Number 124001
    Vancouver, V5Y 3W2, Canada
  • Investigational Site Number 124007
    Vancouver, V5Z 1L8, Canada
  • Investigational Site Number 170004
    Armenia, 630004, Colombia
  • Investigational Site Number 170007
    Barranquilla, 80020, Colombia
  • Investigational Site Number 170001
    Bogota, 110221, Colombia
  • Investigational Site Number 170005
    Bogota, 111311, Colombia
  • Investigational Site Number 170003
    Manizales, 170004, Colombia
  • Investigational Site Number 250004
    Lyon, 69495, France
  • Investigational Site Number 250006
    Nantes Cedex 01, 44093, France
  • Investigational Site Number 250005
    Poitiers Cedex, 86021, France
  • Investigational Site Number 276004
    Dresden, 01307, Germany
  • Investigational Site Number 276003
    Essen, 45359, Germany
  • Investigational Site Number 276001
    München, 81925, Germany
  • Investigational Site Number 276005
    Potsdam, 14469, Germany
  • Investigational Site Number 276002
    Saarlouis, 66740, Germany
  • Investigational Site Number 348004
    Balatonfüred, 8230, Hungary
  • Investigational Site Number 348001
    Budapest, 1036, Hungary
  • Investigational Site Number 348005
    Budapest, 1062, Hungary
  • Investigational Site Number 348007
    Budapest, 1062, Hungary

Showing the first 100 of 162 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ritzel R, Harris SB, Baron H, Florez H, Roussel R, Espinasse M, Muehlen-Bartmer I, Zhang N, Bertolini M, Brulle-Wohlhueter C, Munshi M, Bolli GB. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 2018 Aug;41(8):1672-1680. doi: 10.2337/dc18-0168. Epub 2018 Jun 12. Erratum In: Diabetes Care. 2019 Aug;42(8):1604. doi: 10.2337/dc19-er08. PubMed 29895556 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2014
First posted
Dec 19, 2014
Start
Jan 2015
Primary completionActual
May 2016
CompletionActual
May 2016
Results first posted
Jul 11, 2017
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02320721
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 19, 2014
Start date
Jan 2015
Primary completion
May 2016
Completion
May 2016
Results posted
Jul 11, 2017
Last update
Apr 21, 2020

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion